Study of Docetaxel or Vinorelbine Plus Cisplatin in Neoadjuvant Chemoradiotherapy for Esophageal Cancer (NEOCRTEC308)
- Sponsor
- Sun Yat-sen University
- Study ID
- NCT02465736
- Phase
- PHASE3
- Status
- Unknown
Conditions
- Esophageal Cancer
- Esophageal Squamous Cell Carcinoma
- Oesophageal Cancer
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 70 Years
- Healthy Volunteers
- Not accepted
Interventions
- Docetaxel — DRUG25mg/ m2 Docetaxel dose administered on days 1, 8, 15, and 22.
- Cisplatin — DRUG25mg/ m2 on days 1, 8, 15 and 22.
- Radiation — RADIATIONPatient will receive 4 weeks of radiation therapy (44 Gy/20 fractions).
- Surgery — PROCEDUREMcKeown esophagectomy, Ivor Lewis esophagectomy or minimally invasive esophagectomy will be performed 4-8 weeks after chemoradiotherapy. Two-field lymphadenectomy with total mediastinal lymph node dissection is performed during surgery.
- Vinorelbine — DRUG25mg/ m2 on days 1, 8 of each cycle (i.e. every 21 days).
- Cisplatin — DRUG75mg/ m2 on day 1 of each cycle only (i.e. every 21 days).
Study Details
The primary objective is to compare docetaxel plus cisplatin (DP) versus vinorelbine plus cisplatin (NP) in neoadjuvant chemoradiotherapy, in terms of the overall survival and toxicity in patients with Stage IIB or III squamous cell esophageal carcinoma.
Key Dates
- Start date
- Jul 31, 2015
- Status verified
- Jan 2024
- Primary completion
- Jul 31, 2025
- Completion
- Jul 31, 2025
Study Design
- Enrollment
- 610 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: A (DP-RT)• Arm A consists of the concurrent chemoradiotherapy prior to surgery. The patient will receive 4 weeks of radiation therapy and 4 weekly cycles of chemotherapy. The radiation will generally commence on the 1st day of treatment and will run for 4 weeks. Chemotherapy is given by intravenous infusion on days 1, 8, 15, and 22. Interventions: * Radiation: (44 Gy/20 fractions) * Drug: Docetaxel * Drug: Cisplatin
- Experimental: B (NP-RT)• Arm B consists of the concurrent chemoradiotherapy followed by surgery. The patient will receive 4 weeks of radiation therapy and 2 cycles of chemotherapy. The radiation will generally commence on the 1st day of treatment and will run for 4 weeks. Each cycle of chemotherapy lasts 21 days/3 weeks. The drugs include Vinorelbine and Cisplatin. Interventions: * Radiation: (44 Gy/20 fractions) * Drug: Vinorelbine * Drug: Cisplatin
Primary Outcome Measure
Overall survival [ Time Frame: At end of trial- up to 3 years in follow up ]
Related Studies
- Outcomes After Esophagectomy With a Focus on Minimally Invasive Esophagectomy and Quality of LifeRecruiting · University of Pittsburgh · Pittsburgh, Pennsylvania
- Esophageal Cancer Risk RegistryRecruiting · University of Pittsburgh · Pittsburgh, Pennsylvania
- Gastrointestinal Biomarkers in Tissue and Biological Fluid Samples From Colorectal Cancer PatientsRecruiting · Vanderbilt University Medical Center · Nashville, Tennessee
- Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal VolunteersRecruiting · University of Colorado, Denver · Aurora, Colorado